Puri Raj K. 4

What Happened Puri Raj K., IOVANCE Biotherapeutics' Chief Regulatory Officer, received an award of 117,500 restricted stock units (RSUs) on March 9, 2026. The award is reported as a derivative grant (transaction code A) at $0.00 per unit — i.e., a compensatory RSU grant, not a market purchase or sale.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (reported within the typical two-business-day window).
• Grant: 117,500 RSUs; reported price: $0.00; reported value at grant: $0 (compensatory award).
• Post-transaction ownership: Not specified in the filing.
• Footnotes: Each RSU represents a contingent right to one share. Vesting: one-third on the one-year anniversary of the grant, then the remaining two-thirds vest in eight equal quarterly installments over the following two years (vesting commences the first quarter after the first anniversary).
• Transaction type: Award/Grant (derivative); no sale or purchase of shares occurred.

Context RSUs are compensation that convert into shares if and when vesting conditions are met; they do not indicate an immediate cash investment or sale by the insider. This is a routine executive equity grant used for retention and compensation; it should be interpreted as a future potential issuance of shares upon vesting, not an immediate change in market holdings.